Item 9A. Controls and Procedures
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities and Exchange Act of 1934 is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our President and Chief Executive Officer, who is also serving as our Chief Financial Officer and therefore currently serves as both our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
As of December 31, 2025, our management, with the participation of our Chief Executive Officer, who is also serving as our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As a result of the identified material weakness described below, our principal executive officer and principal financial and accounting officer has concluded based upon the evaluation described above that, as of December 31, 2025, our disclosure controls and procedures were not effective at the reasonable assurance level.
61
Table of Contents
Management’s Report on Internal Control over Financial Reporting
This Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including the individuals serving as our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Management conducted an assessment of the effectiveness of the Company’s internal control over financial reporting based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013 Framework). Based on this assessment, including the existence of the material weakness discussed herein, our management concluded that, as of December 31, 2025, our internal control over financial reporting was not effective based on those criteria.
Material Weakness in Internal Control over Financial Reporting
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
In connection with our first quarter of activity in implementing our new digital asset treasury strategy during the three months ended December 31, 2025, management identified a material weakness in our internal control over financial reporting relating to our failure to maintain effective controls over the accounting for certain complex and unusual transactions. Specifically, the material weakness relates to the operating effectiveness of controls that had been designed and implemented to account for complex and unusual transactions.
We engage external accounting and tax experts to assist with these complex matters. Although our internal controls were sufficiently designed and implemented for complex and unusual transactions, they did not operate effectively.
This control deficiency resulted in errors which were not detected by management’s existing controls. This material weakness did not result in any material misstatements to our consolidated financial statements or any changes to previously filed financial statements.
Remediation Efforts
To remediate this material weakness, our management, under the oversight of the Audit Committee of the Board, has begun and will continue to implement the following remediation plans:
1. Enhanced Oversight: Management is developing and adopting formal procedures to verify the inputs, assumptions, and methodologies used by external specialists with regard to future complex and unusual transactions.
2. Training: Management is providing for specialized training to our existing finance staff regarding the oversight of third-party service providers and specialists regarding any future complex and unusual transactions.
Attestation Report on Internal Control Over Financial Reporting
This Annual Report does not include an attestation report of our independent registered public accounting firm due to our status as a smaller reporting company and non-accelerated filer.
Changes in Internal Control Over Financial Reporting
In connection with the October 2025 Private Placement and our initiation of a digital asset treasury strategy, we implemented digital asset treasury processes and controls during the quarter ended December 31, 2025. There were no other changes to our internal control over financial reporting that occurred during the quarter ended December 31, 2025 covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
62
Table of Contents
Item 9B. Other Information .
N o n e .
Item 9C. Disclosures Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable
63
Table of Contents
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
The Company has adopted an insider trading policy that governs the purchase, sale, and/or other transactions of our securities by our directors, officers and employees. A copy of our insider trading policy is filed as Exhibit 19.1 to this Annual Report on Form 10-K for the fiscal year ended December 31, 2025. In addition, with regard to the Company’s trading in its own securities, it is the Company’s policy to comply with the federal securities laws and the applicable exchange listing requirements.
The remaining information required by this Item is set forth in our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2025, and is incorporated into this Annual Report on Form 10-K by reference.
Item 11. Executive Compensation.
The information required by this Item is set forth in our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2025, and is incorporated into this Annual Report on Form 10-K by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this Item is set forth in our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2025, and is incorporated into this Annual Report on Form 10-K by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
The information required by this Item is set forth in our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2025, and is incorporated into this Annual Report on Form 10-K by reference.
Item 14. Principal Accountant Fees and Services.
The information required by this Item is set forth in our Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2025, and is incorporated into this Annual Report on Form 10-K by reference.
64
Table of Contents
PART IV
Item 15. Exhibits and Financial Statement Schedules.
(a)(1) Financial Statements
The financial statements listed below are filed as part of this Annual Report on Form 10-K.
Report of Independent Registered Public Accounting Firm (PCAOB ID Number 274 )
F-2
Consolidated Balance Sheets as of December 31, 2025 and 2024
F-4
Consolidated Statements of Operations for the Years Ended December 31, 2025 and 2024
F-5
Consolidated Statements of Comprehensive Income (Loss) for the Years Ended December 31, 2025 and 2024
F-6
Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2025 and 2024
F-7
Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024
F-9
Notes to Consolidated Financial Statements
F-10
(a)(2) Financial Statement Schedules
All financial schedules have been omitted because the required information is either presented in the Consolidated Financial Statements or the Notes thereto or is not applicable or required.
(a)(3) Exhibits
The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the exhibits and are incorporated herein by reference.
65
Table of Contents
EXHIBIT INDEX
Exhibit
No.
Description
2.1
Merger Agreement, dated January 17, 2023, by and among Leap Therapeutics, Inc., Fire Merger Sub, Inc., Flame Biosciences LLC, Flame Biosciences, Inc., and the Stockholder Representative named therein (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 23, 2023).
3.1
Fourth Amended and Restated Certificate of Incorporation of Leap Therapeutics, Inc. (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K, as filed on September 10, 2020).
3.2
Certificate of Designation of Special Voting Stock of Leap Therapeutics, Inc. filed with the Secretary of State of the State of Delaware on [January 7, 2020] (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed on January 7, 2020).
3.3
Certificate of Designation of Preferences, Rights and Limitations of Series X Non-Voting Convertible Preferred Stock filed with the Secretary of State of the State of Delaware on January 17, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on January 23, 2023).
3.4
Certificate of Amendment to the Certificate of Designation of Special Voting Stock of Leap Therapeutics, Inc. filed with the Secretary of State of the State of Delaware on March 16, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8 - K filed on March 16, 2023).
3.5
Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation of Leap Therapeutics, Inc. dated June 20, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, as filed on November 13, 2023).
3.6
Certificate of Elimination of the Series X Non - Voting Convertible Preferred Stock of Leap Therapeutics, Inc. dated August 29, 2023 (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10 - Q for the quarter ended September 30, 2023, as filed on November 13, 2023).
3.7
Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation of Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics, Inc.) dated November 12, 2025 (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as filed on November 12, 2025).
3.8
Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation of Cypherpunk Technologies Inc. dated December 15, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 16, 2025).
3.9
Amended and Restated Bylaws of Cypherpunk Technologies Inc. (effective as of November 12, 2025) (incorporated by reference to Exhibit 3.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as filed on November 12, 2025).
4.1
Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to Amendment No. 2 to the Company’s registration statement on Form S-4, as filed on November 16, 2016).
4.2
Form of Series A Coverage Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, as filed on January 7, 2020).
4.3
Form of Series B Coverage Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K, as filed on January 7, 2020).
4.4
Amendment No. 2 to Warrant, by and among Macrocure, the Registrant and certain warrant holders, dated as of January 23, 2017 (incorporated by reference to Exhibit 4.4 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as filed on March 31, 2017).
4.5
Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed on April 11, 2024).
4.6
Form of Common Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed on October 9, 2025).
4.7
Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K as filed on October 9, 2025).
4.8
Waiver and Modification Agreement, dated November 19, 2025, by and between Cypherpunk Technologies Inc. and Winklevoss Treasury Investments, LLC (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed on November 20, 2025).
4.9*
Description of the Registrant’s Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934.
66
Table of Contents
10.1#
Exclusive Option and License Agreement dated as of January 3, 2020, by and between the Company and BeiGene, Ltd. (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as filed on May 14, 2020).
10.2#
License Agreement, between Eli Lilly and Company and Dekkun Corporation, effective as of January 3, 2011 (incorporated by reference to Exhibit 10.4 to the Company’s registration statement on Form S-4, as filed on September 26, 2016).
10.3
Royalty Agreement, between Leap Therapeutics, Inc. and Leap Shareholder Royalty Vehicle, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed on January 26, 2017).
10.4
Letter Agreement, between Leap Shareholder Royalty Vehicle, Inc. and certain Leap stockholders (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, as filed on January 26, 2017).
10.5
Form of Purchase Agreement, dated as of November 14, 2017, by and among Leap Therapeutics, Inc. and the purchasers identified on the schedule thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed on November 17, 2017).
10.6
Securities Purchase Agreement, dated January 3, 2020, by and among the Company and the institutional investors named therein (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed on January 7, 2020).
10.7
Registration Rights Agreement dated as of January 3, 2020, by and between the Company and the persons listed on the attached Schedule A thereto (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K, as filed on January 7, 2020).
10.8
Registration Rights Agreement dated as of January 3, 2020, by and between the Company and the persons listed on the attached Schedule A thereto (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K, as filed on January 7, 2020).
10.9
Form of Indemnification Agreement (filed as Exhibit 10.10 to Amendment No. 1 to the Registrant’s registration statement on Form S-4, as filed on November 2, 2016).
10.10 ˄
Macrocure 2013 Share Incentive Plan (filed as Exhibit 10.4 to the Company’s registration statement on Form S-8, as filed on January 27, 2017).
10.11 ˄
Amendment No. 1 to Macrocure 2013 Share Incentive Plan (filed as Exhibit 10.5 to the Company’s registration statement on Form S-8, as filed on January 27, 2017).
10.12 ˄
Summary Translation of Macrocure 2008 Stock Option Plan stockholders (filed as Exhibit 10.3 to the Registrant’s registration statement on Form S-8, as filed on January 27, 2017).
10.13 ˄
Employment Agreement, by and between the Company and Douglas E. Onsi, dated as of April 10, 2020 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K/A, as filed on April 15, 2020).
10.14 ˄
Executive Employment Agreement and accompanying Employee Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement, by and between Leap and Christopher K. Mirabelli, dated as of August 29, 2016 (incorporated by reference to Exhibit 10.7 to the Company’s registration statement on Form S-4, as filed on September 26, 2016).
10.15 ˄
Executive Employment Agreement and accompanying Employee Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement, by and between Leap and Augustine Lawlor, dated as of August 29, 2016 (incorporated by reference to Exhibit 10.9 to the Company’s registration statement on Form S-4, as filed on September 26, 2016).
10.16 ˄
Employment Agreement, by and between the Company and Cynthia Sirard, dated as of April 10, 2020 (incorporated by reference to Exhibit 10.18 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed on March 12, 2021).
10.17 ˄
Employment Agreement, by and between the Company and John Mark O’ Mahony, dated as of April 10, 2020 (incorporated by reference to Exhibit 10.19 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed on March 12, 2021).
10.18 ˄
Amended and Restated 2012 Equity Incentive Plan of the Registrant (incorporated by reference to Exhibit 10.1 to the Company’s registration statement on Form S-8, as filed on January 27, 2017).
10.19 ˄
Form of Stock Option Grant Notice and Stock Option Agreement under the Registrant’s Amended and Restated 2012 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.2 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as filed on March 31, 2017).
10.20 ˄
2016 Equity Incentive Plan of Leap Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 to the Company’s registration statement on Form S-8, as filed on January 27, 2017).
10.21 ˄
Form of Stock Option Grant Notice and Stock Option Agreement under Leap’s 2016 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.3 to the Company’s registration statement on Form S-4, as filed on November 2, 2016).
67
Table of Contents
10.22 ˄
First Amendment to the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s registration statement on Form S-8, as filed on June 11, 2019).
10.23
Lease, dated November 13, 2018, by and between the Company and Bulfinch Square Limited Partnership (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K, as filed on November 19, 2018).
10.24
First Amendment to Lease by and between Bulfinch Square Limited Partnership and Leap Therapeutics, Inc., dated as of August 17, 2021 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed on November 12, 2021).
10.25
Second Amendment to Lease by and between Bulfinch Square Limited Partnership and Leap Therapeutics, Inc. dated as of October 1, 2021 (incorporated by reference to Exhibit 10.27 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed on March 24, 2023).
10.26
Third Amendment to Lease by and between Bulfinch Square Limited Partnership and Leap Therapeutics, Inc. dated as of May 16, 2022 (incorporated by reference to Exhibit 10.1 to the Company Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed on August 12, 2022).
10.27
Fourth Amendment to Lease by and between Bulfinch Square Limited Partnership and Leap Therapeutics, Inc. dated as of January 3, 2024 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024).
10.28
Fifth Amendment to Lease by and between Bulfinch Square Limited Partnership and Leap Therapeutics, Inc. dated as of July 1, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025) .
10.29
Registration Rights Agreement, dated January 17, 2023, by and among the Company and the Holders (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on January 23, 2023).
10.30 ˄
Leap Therapeutics, Inc. 2022 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company’s registration statement on Form S-8, as filed on August 17, 2022).
10.31 ˄
Amendment No. 1 to Leap Therapeutics, Inc. 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.33 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed on March 18, 2024)
10.32
Continuing Clinical Collaboration Letter Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8 - K, filed with the SEC on March 16, 2023.
10.33 ˄
Second Amendment to Executive Employment Agreement, by and between the Company and Dr. Cynthia Sirard, dated April 3, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8 - K, filed with the SEC on April 7, 2023).
10.34#
Collaboration Agreement, dated August 10, 2020, by and between Adimab, LLC and Flame Biosciences, Inc. (incorporated by reference to Exhibit 10.2 to the Company Quarterly Report on Form 10 - Q for the quarter ended March 31, 2023).
10.35 ˄
Second Amendment to Executive Employment Agreement, dated April 3, 2023, by and between the Company and John Mark O’Mahony (incorporated by reference to Exhibit 10.5 to the Company Quarterly Report on Form 10 - Q for the quarter ended March 31, 2023).
10.36 ˄
Executive Employment Agreement, by and between the Company and Jason S. Baum. (incorporated by reference to Exhibit 10.6 to the Company Quarterly Report on Form 10 - Q for the quarter ended March 31, 2023).
10.37 ˄
First Amendment to Executive Employment Agreement, dated April 3, 2023, by and between the Company and Jason S. Baum. (incorporated by reference to Exhibit 10.7 to the Company Quarterly Report on Form 10 - Q for the quarter ended March 31, 2023).
10.38
Form of Securities Purchase Agreement by and among the Company and the purchasers named therein (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8 - K as filed on April 11, 2024).
10.39
First Amended and Restated Collaboration Agreement, dated April 2, 2024, by and between Adimab, LLC and Leap Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024).
10.40
Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed on October 9, 2025).
10.41
Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed on October 9, 2025).
10.42
Lead Investor Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K as filed on October 9, 2025).
10.43
Consulting Agreement, dated November 11, 2025, by and between the Company and CoinXit Ltd. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed on November 12, 2025).
68
Table of Contents
10.44˄
Restricted Stock Unit Grant Agreement, dated December 23, 2025, by and between the Company and CoinXit Ltd. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed on December 30, 2025).
10.45˄
Executive Employment Agreement, dated November 11, 2025, by and between the Company and William McEvoy (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K as filed on November 12, 2025).
10.46˄
Form of Director Restricted Stock Unit Agreement pursuant to the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K as filed on November 12, 2025).
10.47˄
Form of Director Restricted Stock Unit Agreement pursuant to the 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K as filed on November 12, 2025).
10.48˄
Form of Employee Restricted Stock Unit Agreement pursuant to the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K as filed on November 12, 2025).
10.49˄
Form of Employee Restricted Stock Unit Agreement pursuant to the 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K as filed on November 12, 2025).
10.50˄
2025 Cypherpunk Technologies Inc. Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed on December 16, 2025).
19.1
Insider Trading Policy (incorporated by reference to Exhibit 19.1 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed on March 26, 2025)
21.1*
Subsidiaries of Cypherpunk Technologies Inc.
23.1*
Consent of EisnerAmper LLP related to Cypherpunk Technologies Inc. financial statements.
31.1*
Certification of Principal Executive and Principal Financial Officer Required Under Rule 13a- 14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1* +
Principal Executive and Principal Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97.1
Leap Therapeutics, Inc. Compensation Clawback Policy (incorporated by reference to Exhibit 97.1 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed on March 18, 2024)
101*
The following materials from Cypherpunk Technologies Inc.’s Annual Report on Form 10-K for the year ended December 31, 2025, formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets at December 31, 2025 and 2024, (ii) Consolidated Statements of Operations for the year ended December 31, 2025 and December 31, 2024, (iii) Consolidated Statements of Shareholders’ Equity at December 31, 2025 and December 31, 2024 (iv) Consolidated Statements of Cash Flows for the year ended December 31, 2025 and December 31, 2024, and (v) Notes to Consolidated Financial Statements, tagged as blocks of text.
104
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
*
Exhibits filed herewith
˄
Indicates management contract or compensation plan
#
Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10).
+
This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of the Section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filing.
69
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CYPHERPUNK TECHNOLOGIES INC.
March 16, 2026
By:
/s/ DOUGLAS E. ONSI
Name: Douglas E. Onsi
Title: President, Chief Executive Officer and Chief Financial Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
NAME
TITLE
DATE
Chief Executive Officer, President, Chief
/s/ DOUGLAS E. ONSI
Financial Officer and Director (Principal
March 16, 2026
Douglas E. Onsi
Executive Officer and Principal Financial Officer)
/s/ KHING OEI
Chairman of the Board of Directors
March 16, 2026
Khing Oei
/s/ JAMES CAVANAUGH
Director
March 16, 2026
James Cavanaugh
Director
March 16, 2026
Thomas Dietz
/s/ WILLIAM LI
Director
March 16, 2026
William Li
/s/ JOSEPH LOSCALZO
Director
March 16, 2026
Joseph Loscalzo
/s/ PATRICIA MARTIN
Director
March 16, 2026
Patricia Martin
/s/ NISSIM MASHIACH
Director
March 16, 2026
Nissim Mashiach
/s/ CHRISTIAN RICHARD
Director
March 16, 2026
Christian Richard
/s/ RICHARD L. SCHILSKY
Director
March 16, 2026
Richard L Schilsky
/s/ CHRISTOPHER K. MIRABELLI
Director
March 16, 2026
Christopher K. Mirabelli
/s/ WILLIAM MCEVOY
Director
March 16, 2026
William McEvoy
70
Table of Contents
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Page
Report of Independent Registered Public Accounting Firm (PCAOB ID 274)
F-2
Consolidated Balance Sheets as of December 31, 2025 and 2024
F-4
Consolidated Statements of Operations for the Years Ended December 31, 2025 and 2024
F-5
Consolidated Statements of Comprehensive Income (Loss) for the Years Ended December 31, 2025 and 2024
F-6
Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2025 and 2024
F-7
Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024
F-9
Notes to Consolidated Financial Statements
F-10
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
Cypherpunk Technologies Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc.) and Subsidiaries (the “ Company ” ) as of December 31, 2025 and 2024, and the related consolidated statements of operations, comprehensive income (loss), stockholders ’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “ financial statements ” ). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2025 and 2024, and the consolidated results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company ’ s management. Our responsibility is to express an opinion on the Company ’ s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ( “ PCAOB ” ) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company ’ s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Evaluation of Control and Accounting for Digital Assets Held by a Custodian
As discussed in Note 2 – Digital Assets Receivable to the consolidated financial statements, as of December 31, 2025, the Company held a material balance of digital assets acquired as part of a newly implemented digital asset treasury strategy. These digital assets are held by a third-party custodian, which is a related party of the Company. Management exercised significant judgment in determining whether the Company controls the digital assets for financial reporting purposes and the appropriate accounting and presentation through evaluating the terms of the custodial agreement, assessing the Company ’ s contractual rights to the assets, and interpreting and applying the authoritative accounting guidance and the impact of the assets being held in commingled or omnibus wallets.
F-2
Table of Contents
We identified the assessment of control over the digital assets and the appropriate accounting and presentation as a critical audit matter because it involved complex judgment, significant management assumptions and extensive audit effort and because the conclusions directly affect the recognition, presentation and disclosure of a material balance in the consolidated financial statements.
Addressing the critical audit matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. Our audit procedures related to this matter included:
● Obtaining an understanding of and evaluating the design and implementation of controls over the digital assets process for accounting purposes.
● Evaluating management ’ s application of authoritative accounting guidance, including considerations regarding control of the digital assets and contemplation of the related-party nature of the custodial arrangement in accordance with U.S. GAAP.
● Inspecting the custodial agreement to assess the Company ’ s contractual rights, including its ability to transfer, withdraw or otherwise direct the use of the digital assets.
● Assessing whether any contractual restrictions or protective rights held by the custodian substantively limit the Company ’ s control over the digital assets.
● Obtaining direct confirmation from the custodian regarding, ownership attribution and the Company ’ s rights to the assets held.
● Evaluating the implications of the assets being held in commingled or omnibus wallets, including reviewing the custodian ’ s SOC1 Type II report to understand relevant controls over customer account balances.
● Assessing the adequacy of the Company ’ s financial statement disclosures related to digital assets, custodial arrangements and related-party relationships.
/s/ EisnerAmper LLP
We have served as the Company’s auditor since 2014.
EISNERAMPER LLP
Philadelphia, Pennsylvania
March 16, 2026
F-3
Table of Contents
CYPHERPUNK TECHNOLOGIES INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
December 31,
December 31,
2025
2024
Assets
Current assets:
Cash and cash equivalents
$
14,035
$
47,249
Digital assets receivable
147,404
—
Research and development incentive receivable
602
704
Prepaid expenses and other current assets
40
86
Total current assets
162,081
48,039
Right of use assets, net
38
262
Deferred costs
401
—
Deposits
662
823
Total assets
$
163,182
$
49,124
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$
1,981
$
4,743
Accrued expenses
2,067
8,536
Income tax payable
472
531
Lease liability
38
266
Total current liabilities
4,558
14,076
Non-current liabilities:
Deferred tax liability
5,118
—
Total liabilities
9,676
14,076
Stockholders’ equity:
Preferred stock, $ 0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively
—
—
Common stock, $ 0.001 par value; 490,000,000 and 240,000,000 shares authorized; 83,851,051 and 38,329,894 shares issued and outstanding as of December 31, 2025 and 2024, respectively
84
38
Stock subscription receivable
( 150 )
—
Additional paid-in capital
616,216
502,501
Accumulated other comprehensive loss
( 95 )
( 120 )
Accumulated deficit
( 462,549 )
( 467,371 )
Total stockholders’ equity
153,506
35,048
Total liabilities and stockholders’ equity
$
163,182
$
49,124
See notes to consolidated financial statements
F-4
Table of Contents
CYPHERPUNK TECHNOLOGIES INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
Year Ended December 31,
2025
2024
Operating expenses:
Research and development
$
25,670
$
57,211
General and administrative
10,870
12,846
Restructuring charges
4,527
—
Total operating expenses
41,067
70,057
Loss from operations
( 41,067 )
( 70,057 )
Interest income
916
3,129
Interest expense
( 24 )
—
Australian research and development incentives
( 157 )
—
Change in fair value of embedded derivative
50,404
—
Foreign currency gain (loss)
5
( 42 )
Income (loss) before income taxes
10,077
( 66,970 )
Provision for income taxes
( 5,255 )
( 585 )
Net income (loss)
4,822
( 67,555 )
Dividend attributable to down round feature of warrants
—
( 234 )
Net income (loss) attributable to common stockholders
$
4,822
$
( 67,789 )
Net income (loss) per share
Basic
$
0.07
$
( 1.81 )
Diluted
$
0.07
$
( 1.81 )
Weighted average common shares outstanding
Basic
66,140,346
37,550,677
Diluted
70,672,358
37,550,677
See notes to consolidated financial statements
F-5
Table of Contents
CYPHERPUNK TECHNOLOGIES INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)
Year Ended December 31,
2025
2024
Net income (loss)
$
4,822
$
( 67,555 )
Other comprehensive income (loss):
Foreign currency translation adjustments
25
( 226 )
Comprehensive income (loss)
$
4,847
$
( 67,781 )
See notes to consolidated financial statements
F-6
Table of Contents
CYPHERPUNK TECHNOLOGIES INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
FOR THE YEAR ENDED DECEMBER 31, 2024
(In thousands, except share amounts)
Stockholders Equity
Accumulated
Additional
Other
Total
Common Stock
Paid-in
Comprehensive
Accumulated
Stockholders’
Shares
Amount
Capital
Income (loss)
Deficit
Equity
Balances at December 31, 2023
25,565,414
$
26
$
459,591
$
106
$
( 399,582 )
$
60,141
Issuance of common stock upon vest of restricted stock units
27,500
—
—
—
—
—
Issuance of common stock upon exercise of stock options
34,698
—
92
—
—
92
Issuance of common stock upon exercise of warrants
41,289
—
41
—
—
41
April 2024 Private Placement (net of issuance costs of $ 2,948 )
12,660,993
12
37,039
—
—
37,051
Dividend attributable to the down round feature of 2017 Warrants
—
—
234
—
( 234 )
—
Foreign currency translation adjustment
—
—
—
( 226 )
—
( 226 )
Stock-based compensation
—
—
5,504
—
—
5,504
Net loss
—
—
—
—
( 67,555 )
( 67,555 )
Balances at December 31, 2024
38,329,894
$
38
$
502,501
$
( 120 )
$
( 467,371 )
$
35,048
See notes to consolidated financial statements
F-7
Table of Contents
CYPHERPUNK TECHNOLOGIES INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
FOR THE YEAR ENDED DECEMBER 31, 2025
(In thousands, except share amounts)
y
Accumulated
Stock
Additional
Other
Total
Common Stock
Subscription
Paid-in
Comprehensive
Accumulated
Stockholders’
Shares
Amount
Receivable
Capital
Loss
Deficit
Equity
Balances at December 31, 2024
38,329,894
$
38
$
—
$
502,501
$
( 120 )
$
( 467,371 )
$
35,048
October 2025 Private Placement (net of issuance costs of $ 1,718 )
15,212,311
15
—
57,155
—
—
57,170
Issuance of common stock through ATM sales
27,151,211
27
—
51,791
—
—
51,818
ATM issuance costs
—
—
—
( 143 )
—
—
( 143 )
Issuance of common stock upon exercise of stock options
6,667
—
—
16
—
—
16
Issuance of common stock upon exercise of prefunded warrants
2,921,041
3
—
( 3 )
—
—
—
Issuance of common stock upon vesting of restricted stock units
229,927
1
—
—
—
—
1
Stock subscription receivable from the issuance of common stock through ATM sales
—
—
( 150 )
—
—
—
( 150 )
Foreign currency translation adjustment
—
—
—
—
25
—
25
Stock-based compensation
—
—
—
4,899
—
—
4,899
Net income
—
—
—
—
—
4,822
4,822
Balances at December 31, 2025
83,851,051
$
84
$
( 150 )
$
616,216
$
( 95 )
$
( 462,549 )
$
153,506
See notes to consolidated financial statements
F-8
Table of Contents
CYPHERPUNK TECHNOLOGIES INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Year Ended December 31,
2025
2024
Cash flows from operating activities:
Net income (loss)
$
4,822
$
( 67,555 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
—
5
Non-cash operating lease expense
224
415
Deferred income taxes
5,118
—
Stock-based compensation expense
4,899
5,504
Change in fair value of embedded derivative
( 50,404 )
—
Foreign currency (gain) loss
( 5 )
42
Changes in operating assets and liabilities:
Prepaid expenses and other assets
1,019
100
Research and development incentive receivable
149
—
Accounts payable and accrued expenses
( 10,421 )
902
Income tax payable
( 95 )
562
Lease liability
( 228 )
( 417 )
Other assets
1,020
143
Net cash used in operating activities
( 43,902 )
( 60,299 )
Cash flows from investing activities:
Purchases of digital assets
( 97,000 )
—
Net cash used in investing activities
( 97,000 )
—
Cash flows from financing activities:
Proceeds from October 2025 Private Placement, net of issuance costs
57,170
—
Proceeds through issuance of common stock through ATM sales, net of fees
51,525
—
Proceeds from April 2024 Private Placement
—
39,999
Payment of deferred offering costs
( 622 )
( 2,948 )
Priciple payments of insurance financing
( 440 )
—
Proceeds from the exercise of warrants
—
41
Proceeds from the exercise of stock options
16
92
Net cash provided by financing activities
107,649
37,184
Effect of exchange rate changes on cash and cash equivalents
39
( 279 )
Net decrease in cash and cash equivalents
( 33,214 )
( 23,394 )
Cash and cash equivalents at beginning of year
47,249
70,643
Cash and cash equivalents at end of year
$
14,035
$
47,249
Supplemental disclosure of non-cash financing activities:
Remeasurement of right-of-use asset and lease liability
$
—
$
420
Dividend attributable to the down round feature of 2017 Warrants
$
—
$
234
Prepayment of insurance through third-party financing
$
440
$
—
Deferred offering costs included in accounts payable
$
638
$
—
Issuance of common stock in exchange for stock subscription receivable
$
150
$
—
See notes to consolidated financial statements
F-9
Table of Contents
CYPHERPUNK TECHNOLOGIES INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
1. Nature of Business, Basis of Presentation and Liquidity
Nature of Business
Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc.) (“the Company”) was incorporated in the state of Delaware on January 3, 2011. Wholly owned subsidiaries of the Company as of December 31, 2025 include HealthCare Pharmaceuticals Pty Ltd. (“HCP Australia”), Leap Securities Corp., Flame Biosciences LLC and Leap Therapeutics, Inc.
Historically, the Company has been a biopharmaceutical company developing biomarker-targeted antibody therapies designed to treat patients with cancer. The Company’s clinical stage program is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. The Company also has a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
The Company has historically devoted substantially all of its resources to development efforts relating to its product candidates, including manufacturing and conducting clinical trials of its product candidates, providing general and administrative support for these operations and protecting its intellectual property. The Company does not have any products approved for sale and has not generated any revenue from product sales. The Company has funded its operations primarily through proceeds from its sales of common stock and preferred stock and proceeds from the issuance of notes payable.
In October 2025, the Company announced a $ 58,888 private placement, led by Winklevoss Capital, and the intent to initiate a digital asset treasury strategy. Immediately following the Closing Date, the Company initiated a strategy to deploy a portion of its capital raised that is not required to provide working capital for its ongoing operations to accumulate digital assets, focused on Zcash. Zcash is a protocol and blockchain network of connected devices all over the world, working together to validate transactions and maintain the Zcash ledger. ZEC is the monetary unit, or coin, of Zcash. Zcash allows for greater privacy, providing users with options for fully shielded transactions in which the sender, recipient, and amount are encrypted.
On November 12, 2025, the Company changed its name from “Leap Therapeutics, Inc.” to “Cypherpunk Technologies Inc.” and changed its trading symbol from “LPTX” to “CYPH”. The Company was renamed to Cypherpunk Technologies Inc. to reflect the strategic focus on acquiring ZEC, participating in the development of Zcash, and the values of privacy and liberty. The Company’s ongoing research and development operations is being conducted under a new wholly-owned subsidiary named “Leap Therapeutics, Inc.”, which was incorporated in November 2025.
Basis of Presentation
The accompanying consolidated financial statements of the Company include the accounts of its wholly owned subsidiaries and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
Liquidity
Since inception, the Company has been engaged in organizational activities, including raising capital, and research and development activities, and in October 2025, the Company implemented its digital asset treasury strategy. The Company has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations, and the Company does not have a product that has been approved by the Food and Drug Administration (the “FDA”). There is no assurance that profitable operations from the Company’s privacy technology/digital asset treasury strategy or biotechnology research and development operations, if achieved, could be sustained on a continuing basis. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital, the success of the privacy technology/digital asset treasury strategy, its biotechnology research and commercialization efforts, regulatory approval, and, ultimately, the market acceptance of the Company’s products.
F-10
Table of Contents
In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. As of December 31, 2025, the Company had cash and cash equivalents of $ 14,035 . Additionally, the Company had an accumulated deficit of $ 462,549 at December 31, 2025, and during the year ended December 31, 2025, the Company incurred net operating losses of $ 41,067 . The Company expects to continue to generate operating losses for the foreseeable future.
The Company believes that its cash and cash equivalents of $ 14,035 as of December 31, 2025 will be sufficient to fund its operating expenses for at least 12 months from the issuance of these financial statements.
In addition, to support its future operations and recently announced digital asset treasury strategy, the Company will likely seek additional funding through public or private equity financings or government programs, and, for its biotechnology operations, will likely seek funding or development program cost-sharing through collaboration agreements or licenses with larger pharmaceutical or biotechnology companies. The inability to obtain funding, as and when needed, could have a negative impact on the Company’s financial condition and ability to pursue its business strategies.
2. Summary of Significant Accounting Policies
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions are eliminated upon consolidation.
Use of Estimates
The presentation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash equivalents consisted of overnight investments and money market funds.
Digital Assets Receivable
As part of its digital asset strategy, the Company holds digital assets in the form of Zcash with Gemini Space Sciences LLC, a third-party custodian (“Gemini”). The Company does not control the digital assets for accounting purposes, and the contractual arrangement represents the Company’s enforceable contractual right to receive digital assets from the custodian on demand and is accounted for as a hybrid instrument under ASC 815, Derivatives and Hedging (“ASC 815”). The host contract represents a non-interest bearing receivable collectible on demand and is recorded at the transaction price, representing the fair value of the digital assets at the time of acquisition, and was $ 97,000 as of December 31, 2025.
The hybrid instrument contains an embedded derivative that is required to be bifurcated because the embedded exposure to changes in the fair value of the underlying digital assets is not clearly and closely related to the economic characteristics of the host receivable. The embedded derivative is subsequently measured at the fair value each reporting period, with changes in fair value recorded as an unrealized gain (loss) on change in fair value of embedded derivative in the Consolidated Statement of Operations. During the year ended December 31, 2025, the Company recorded an unrealized gain on change in fair value of embedded derivative of $ 50,404 .
As digital assets receivable is collectible on demand, it’s classified as a current asset on the Company’s consolidated balance sheet. As of December 31, 2025, the Company had digital assets receivable of $ 147,404 .
F-11
Table of Contents
Research and Development Expense
Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including noncash share-based compensation and costs for third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, patient enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered.
Research and development incentive income and receivable
The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian Government’s support for Australia’s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997 as long as eligibility criteria are met.
Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end management estimates the refundable tax offset available to the Company based on available information at the time. This estimate is also reviewed by external tax advisors on an annual basis.
Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia is reimbursed. This percentage was 43.5 % for the years ended December 31, 2025 and 2024.
The research and development incentive receivable represents an amount due in connection with the above program. The Company has recorded a research and development incentive receivable of $ 602 and $ 704 as of December 31, 2025 and 2024, respectively, in the consolidated balance sheets. The Company did no t record any income from Australian research and development incentives during the year ended December 31, 2024. During the year ended December 31, 2025, the Company recorded expense of $ 157 from Australian research and development incentives.
The following table shows the change in the research and development incentive receivable from January 1, 2024 to December 31, 2025:
Balance at January 1, 2024
$
771
Foreign currency translation
( 67 )
Balance at December 31, 2024
704
Australian research and development incentives
( 157 )
Foreign currency translation
55
Balance at December 31, 2025
$
602
Concentration of Credit Risk
Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents. All cash and cash equivalents are held in United States or Australian financial institutions and money market funds. At times, the Company may maintain cash balances in excess of the federally insured amount of $250 per depositor, per insured bank, for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the years ended December 31, 2025 and 2024.
F-12
Table of Contents
As of December 31, 2025, the Company also had digital assets receivable of $ 147,404 , representing approximately 90 % of the Company’s total assets. The Company’s digital assets are maintained with a single third-party, Gemini (see Note 15) . These digital assets are recorded as digital assets receivable on the consolidated balance sheet. Because custody is concentrated with a single counterparty, the Company is exposed to credit risk, liquidity risk, operational risk, and counterparty performance risk.
Digital assets held with Gemini are not insured by the Federal Deposit Insurance Corporation (“FDIC”), the Securities Investor Protection Corporation (“SIPC”), or any other governmental insurance program , and recovery of such assets in the event of Gemini’s insolvency or failure may be uncertain. The Company monitors Gemini’s financial condition and operational controls on an ongoing basis; however, there can be no assurance that the Company would be able to recover some or all of its digital assets if Gemini were unable to fulfill its obligations, experiences financial difficulty, or becomes subject to regulatory, cybersecurity, or operational disruptions.
Income Taxes
The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
The Company follows accounting guidance concerning provisions for uncertainty in income tax positions. This guidance clarifies the accounting for income taxes by prescribing a minimum probability threshold that an uncertain tax position must meet before a financial statement benefit is recognized. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement.
The Company recognizes accrued interest and penalties associated with uncertain tax position as part of the income tax provision. There were no uncertain tax positions or income tax related interest and penalties recorded for the years ended December 31, 2025 and 2024. The income tax returns of the Company for the year ended December 31, 2020 and subsequent years are subject to examination by the Internal Revenue Service and other taxing authorities, generally for three years after the return is filed.
Restructuring Charges
On June 23, 2025, the Company’s Board of Directors approved a series of measures to conserve cash and reduce operating costs, including (i) the completion of the DeFianCe clinical trial and the wind-down of the Company’s research and development activities, including the Company’s sirexatamab and FL-501 development programs, and (ii) a reduction in force that impacted approximately 75 % of the Company’s workforce. The reduction in force was conducted in two phases (i) first, on June 30, 2025, that impacted the Company’s Chief Operating Officer, Chief Scientific Officer and Chief Manufacturing Officer and (ii) second, on July 31, 2025 that impacted the Chief Medical Officer of the Company. As a result of this workforce reduction, during the year ended December 31, 2025, the Company incurred $ 4,527 of charges recorded within restructuring charges in the consolidated statements of operations. The Company does not expect to incur any further material charges related to this workforce reduction. The charges consist primarily of one-time employee severance and benefit costs and stock-based compensation expense related to acceleration of vesting. As of December 31, 2025, $ 1,461 is accrued within accrued expenses for employee severance benefits.
Foreign Currency Translation
The financial statements of the Company’s foreign subsidiary are measured using the local currency as the functional currency. Assets and liabilities of this subsidiary are translated into U.S. dollars at exchange rates as of the consolidated balance sheet date. Equity is translated at historical exchange rates. Revenues and expenses are translated into U.S. dollars at average rates of exchange in effect during the year. The resulting cumulative translation adjustments have been recorded as a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in the results of operations.
F-13
Table of Contents
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Computer equipment is depreciated over three years . Laboratory equipment , office equipment and furniture and fixtures are depreciated over five years . Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.
Impairment of Long-Lived Assets
Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value. The Company did not record any impairment losses on long-lived assets during 2025 and 2024.
Deferred Costs
The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering.
As of December 31, 2025, there was $ 401 of deferred offering costs. The Company did no t have any deferred costs as of December 31, 2024.
Deposits
Deposits as of December 31, 2025 and 2024 included $ 662 and $ 823 , respectively, of deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized.
Warrants
The Company will recognize on a prospective basis the value of the effect of the down round feature in the warrants to purchase shares of common stock that were issued in a private placement in November 2017 (the “2017 Warrants”) when it is triggered (i.e., when the exercise price is adjusted downward). This value is measured as the difference between (1) the financial instrument’s fair value (without the down round feature) using the pre-trigger exercise price and (2) the financial instrument’s fair value (with the down round feature) using the reduced exercise price. The value of the effect of the down round feature will be treated as a dividend and a reduction to income available to common stockholders in the basic EPS calculation. In connection with the private placement of common stock and prefunded warrants completed in April 2024 (the “April 2024 Private Placement”), when the 2017 Warrants were repriced from $ 10.55 to $ 2.82 as a result of a down round, the Company recorded a dividend of $ 234 during the year ended December 31, 2024. The 2017 Warrants expired in November 2024.
F-14
Table of Contents
Fair Value of Financial Instruments
Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
● Level 1—Quoted prices in active markets for identical assets or liabilities.
● Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
● Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
During the years presented, the Company has not changed the manner in which it values assets and liabilities that are measured at fair value using Level 3 inputs. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the years ended December 31, 2025 and 2024.
A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows (in thousands):
Total
Level 1
Level 2
Level 3
December 31, 2025
Assets:
Cash equivalents
$
10,777
$
10,777
$
—
$
—
Digital assets receivable
$
147,404
$
147,404
$
—
Total assets
$
158,181
$
158,181
$
—
$
—
December 31, 2024
Assets:
Cash equivalents
$
23,299
$
23,299
$
—
$
—
Total assets
$
23,299
$
23,299
$
—
$
—
Cash equivalents of $ 10,777 and $ 23,299 as of December 31, 2025 and 2024, respectively, consisted of overnight investments and money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.
The fair value of the embedded derivative associated with Digital assets receivable is measured using the ask (best sell price) as of 11.00 p.m. Eastern Standard Time on the last day of the reporting period for Zcash in active markets in which the Company transacts. As the Digital assets receivable is collectible on demand, its fair value is directly based on observable market prices for the underlying digital asset without adjustment for credit risk, duration, or other entity-specific assumptions. Accordingly, the embedded derivative is classified within Level 1 of the fair value hierarchy under ASC 820, as its fair value is determined using quoted prices for identical assets in active markets.
The carrying value of the research and development incentive receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these assets and liabilities.
F-15
Table of Contents
Leases
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. All leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize leases on the balance sheet with terms of one year or less. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. The Company has determined that the rate implicit in the lease is not determinable and the Company does not have borrowings with similar terms and collateral. Therefore, the Company considered a variety of factors, including observable debt yields from comparable companies and the volatility in the debt market for securities with similar terms, in determining that 8 % was reasonable to use as the incremental borrowing rate for purposes of the calculation of lease liabilities.
In accordance with the guidance in ASC 842 “Leases”, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components.
Although separation of lease and non-lease components is required, certain practical expedients are available. Entities may elect the practical expedient to not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease component together as a single component. The Company has elected to account for the lease and non-lease components of each of its operating leases as a single lease component and allocate all of the contract consideration to the lease component only. The lease component results in an operating right-of-use asset being recorded on the consolidated balance sheets and amortized such that lease expense is recorded on a straight line basis over the term of the lease.
Segment Information
The Company’s chief operating decision maker (“CODM”), the Chief Executive Officer, manages the Company’s business activities as a single operating and reportable segment at the consolidated level. Accordingly, the Company’s CODM uses consolidated net income (loss) to measure segment income (loss), allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (research and development and general and administrative) at the consolidated level to manage the Company’s operations. Other segment items included in consolidated net income (loss) are interest income and foreign currency gain (loss), which are reflected in the consolidated statements of operations and comprehensive income (loss).
Patent Costs
All patent related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.
Stock-Based Compensation
The Company measures stock options and restricted stock units (“RSUs”) granted to employees, consultants and nonemployees based on the fair value on the date of the grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. Generally, the Company issues stock options and RSUs with only service-based vesting conditions and records the expense for these awards using the straight-line method.
Stock-based compensation is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided.
The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The expected volatility is based on the historical volatility of the Company. The expected term of the Company’s stock options granted to employees has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to nonemployees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield of zero is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.
F-16
Table of Contents
The Company expenses the grant date fair value of employee RSUs over the associated employee service period on a straight-line basis. Stock-based compensation expense is determined based on the fair value of the award at the grant date and is adjusted each period to reflect actual forfeitures.
Net Income (Loss) per Share
Basic net income (loss) per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed using the weighted average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common stock, including the assumed exercise of stock options and warrants.
Subsequent Events
The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required.
Recently Issued Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified date.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), and in January 2025, the FASB issued Accounting Standards Update No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date (“ASU 2025-01”). ASU 2024-03 requires additional disclosure of the nature of expenses included in the income statement as well as disclosures about specific types of expenses included in the expense captions presented in the income statement. ASU 2024-03, as clarified by ASU 2025-01, will be effective for annual reporting periods beginning after December 15, 2026 on a prospective basis. Both early adoption and retrospective application are permitted. The Company is currently evaluating the impact that the adoption of these standards will have on its consolidated financial statements and disclosures.
Recently Adopted Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-08, Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60), which requires certain crypto assets to be measured at fair value with changes recognized in net income and mandates additional disclosures. The Company adopted ASU 2023-08 effective January 1, 2025, but it had no impact on the financial statements during the year ended December 31, 2025.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU No. 2023-09 requires a public business entity (“PBE”) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December 15, 2024. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December 31, 2025 and continuing to provide the pre-ASU disclosures for the prior periods or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of January 1, 2025, the Company adopted this new ASU, and it only impacts the Company’s income tax disclosures (see Note 11) with no impact to its operations, cash flows, or financial condition.
F-17
Table of Contents
3. Digital Assets Receivable
As part of its digital asset treasury strategy, the Company acquired 290,062.67 ZEC tokens at a weighted average cost of $ 334.41 per token, for an aggregate purchase price of $ 97,000 during the year ended December 31, 2025. The acquired digital assets are held with Gemini, a third-party exchange and custodian, and the arrangement is accounted for as a hybrid instrument consisting of (i) a host contract representing the right to receive digital assets on demand, and (ii) an embedded derivative indexed to changes in the fair value of the underlying digital assets.
Digital assets receivable is initially recorded at the transaction price and the embedded derivative is subsequently measured at the fair value of the underlying digital assets to be received. Changes in fair value of the embedded derivative are recognized as unrealized gains (losses) on the change in fair value of embedded derivative in the consolidated statement of operations. The carrying value of the host contract and the embedded derivative as of December 31, 2025, was $ 97,000 , and $ 50,404 , respectively, which are presented together as digital assets receivable on the accompanying consolidated balance sheet.
The balance of digital assets receivable was $ 147,404 as of December 31, 2025. The Company recorded an unrealized gain on embedded derivative of $ 50,404 during the year ended December 31, 2025.
4. Stock Subscription Receivable
During the year ended December 31, 2025, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), pursuant to which the Company may offer and sell shares of its common stock, par value $ 0.001 per share, having an aggregate offering price of up to $ 200,000 from time to time to or through Cantor, acting as principal and/or sales agent. See Note 9.
In connection with the Sales Agreement, the Company issued 122,000 shares of its common stock on December 31, 2025, for net proceeds of $ 150 . As the Company did not receive the proceeds until January 2026, it recorded a stock subscription receivable of $ 150 in its consolidated balance sheet as of December 31, 2025.
5. Property and equipment, net
Property and equipment, net consisted of the following:
December 31,
2025
2024
Computer office equipment
$
51
$
51
Leasehold improvements
69
69
Lab equipment
76
76
Furniture and fixtures
30
30
226
226
Less: accumulated depreciation
( 226 )
( 221 )
Property and equipment, net
$
—
$
5
Depreciation expense was $ 5 for the year ended December 31, 2024. The Company did no t record depreciation expense during the year ended December 31, 2025.
F-18
Table of Contents
6. Accrued Expenses
Accrued expenses consist of the following:
December 31,
2025
2024
Clinical trials
$
98
$
4,798
Professional fees
203
274
Payroll and related expenses
305
3,464
Severance
1,461
—
Accrued expenses
$
2,067
$
8,536
7. Leases
The Company has an operating lease for real estate in the United States and does not have any finance leases. The Company’s leases may contain options to renew and extend lease terms and options to terminate leases early. Reflected in the right-of-use asset and lease liability on the Company’s consolidated balance sheets are the periods provided by renewal and extension options that the Company is reasonably certain to exercise, as well as the periods provided by termination options that the Company is reasonably certain to not exercise.
The Company’s existing lease agreement for the premises located at 47 Thorndike Street (the “47 Thorndike Street Lease”) was set to expire on July 31, 2025. On July 1, 2025 the Company entered into a Fifth Amendment to Lease (“Fifth Amendment”) with Landlord, extending the 47 Thorndike Street Lease as a tenancy-at will (as amended, the “Lease”). The term of the Lease expires on the later of August 31, 2025 or the last day of any month identified by notice by the Company or Landlord to the other, not less than sixty ( 60 ) days in advance. The Lease includes variable lease and non-lease components that are not included in the right-of-use asset and lease liability and are reflected as an expense in the period incurred. Such payments primarily include common area maintenance charges.
In calculating the present value of future lease payments, the Company utilized its incremental borrowing rate based on the lease term. The Company has an existing net lease in which the non-lease components (e.g. common area maintenance, maintenance, consumables, etc.) are paid separately from rent based on actual costs incurred and therefore are not included in the right-of-use asset and lease liability and are reflected as an expense in the period incurred. During the year ended December 31, 2024, the Company extended the term of its operating lease to July 31,2025 and recorded an additional right-of-use asset and lease liability of $ 420 and during the year ended December 31, 2025, the Company extended the term of its operating lease as a tenancy-at-will, with the term expiring on the later of August 31, 2025 or the last day of any month identified by notice by the Company or Landlord to the other, not less than sixty ( 60 ) days in advance, and recorded an additional right of-of-use asset and lease liability of $ 38 . As of December 31, 2025, a right-of-use asset of $ 38 and lease liability of $ 38 are reflected on the consolidated balance sheet. The Company recorded rent expense of $ 372 and $ 461 , respectively, during the years ended December 31, 2025 and 2024. Cash paid for amounts included in the measurement of lease liabilities was $ 349 and $ 463 , respectively, during the years ended December 31, 2025 and 2024.
Future lease payments under non-cancelable operating leases as of December 31, 2025 are $ 38 .
F-19
Table of Contents
8. Warrants
As of December 31, 2025, outstanding warrants to purchase common stock, all of which are classified as equity warrants, consisted of the following:
December 31, 2025
Number of Common Shares
Description
Issuable
Exercise Price
Expiration Date
January 23, 2017 Warrants
5,450
$
0.10
Upon M&A Event
2019 Warrants
690,813
$
19.50
February 2026
March 2020 Coverage Warrants
1,921,854
$
21.10
Jan - March 2027
October 2025 Pre-funded Warrants
80,768,504
$
0.001
No Expiry
October 2025 Common Warrants
75,985,605
$
0.5335
October 2032
159,372,226
2017 Warrants
The 2017 Warrants contained full ratchet anti-dilution protection provisions. The Company recognized on a prospective basis the value of the effect of the down round feature in the warrant when it was triggered (i.e., when the exercise price was adjusted downward). This value was measured as the difference between (1) the financial instrument’s fair value (without the down round feature) using the pre-trigger exercise price and (2) the financial instrument’s fair value (with the down round feature) using the reduced exercise price. The value of the effect of the down round feature was treated as a dividend and a reduction to income available to common stockholders in the basic EPS calculation. In connection with the April 2024 Private Placement, when the 2017 Warrants were repriced from $ 10.55 to $ 2.82 , the Company recorded a dividend of $ 234 during the year ended December 31, 2024. The 2017 Warrants expired in November 2024.
March 2020 Pre-funded Warrants
During the year ended December 31, 2025, 824,718 March 2020 Pre-funded Warrants were cashless exercised, resulting in the issuance of 809,558 common shares of the Company’s common stock.
September 2021 Pre-funded Warrants
During the year ended December 31, 2025, 591,603 September 2021 Pre-funded warrants were cashless exercised, resulting in the issuance of 590,424 common shares of the Company’s common stock.
April 2024 Pre-funded Warrants
During the year ended December 31, 2025, 1,523,404 April 2024 Pre-funded Warrants were cashless exercised, resulting in the issuance of 1,521,059 common shares of the Company’s common stock.
January 2023 Common Stock Warrants
In January 2023, pursuant to the Flame Merger, the warrants held by the Flame Warrant Holders became exercisable for 6,530 shares of the Company’s common stock (the “January 2023 Common Stock Warrants”). The January 2023 Common Stock Warrants had an exercise price of $ 6.78 per share and expired in February 2025.
January 2023 Series X Preferred Stock Warrants
In January 2023, pursuant to the Flame Merger, the warrants held by the Flame Warrant Holders also became exercisable for 443 shares of Series X Preferred Stock (the “January 2023 Series X Preferred Stock Warrants”). Following Stockholder Approval, each share of Series X Preferred Stock converted into 100 shares of common stock during the three months ended June 30, 2023. The January 2023 Series X Preferred Stock Warrants had an exercise price of $ 6.78 per share and expired in February 2025.
F-20
Table of Contents
October 2025 Pre-funded Warrants
In connection with the October 2025 Private Placement, the Company issued pre-funded warrants (the “October 2025 Pre-Funded Warrants”) to purchase up to an aggregate of 80,768,504 shares of the Company’s common stock. The October 2025 Pre-Funded Warrants have an exercise price of $ 0.001 per share, each exercisable for one share of the Company’s common stock. The exercise price and the number of shares of Common Stock issuable upon exercise of each pre-funded warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock combinations, or similar events affecting the common stock. The October 2025 Pre-Funded Warrants qualify for equity classification.
October 2025 Common Stock Warrants
In connection with the October 2025 Private Placement, the Company issued common warrants (the “October 2025 Common Warrants”) to purchase up to an aggregate of 75,985,605 shares of Company common stock, each exercisable for one share of common stock at an exercise price of $ 0.5335 per common warrant share. The October 2025 Common Warrants are exercisable in cash or by means of a cashless exercise. They expire on the tenth anniversary of their date of issuance and qualify for equity classification. The exercise price and the number of shares of common stock issuable upon exercise of each common warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock combinations, or similar events affecting the common stock.
Parcrest International (“Parcrest”) served as the Company’s placement agent in connection with the October 2025 Private Placement. The Company agreed to pay Parcrest $ 1,500 , as follows: (a) $ 1,000 in cash and (b) October 2025 Common Warrants to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $ 0.5335 per share (the “Placement Agent Warrants”). Parcrest has agreed that it shall not sell, transfer, assign, pledge, or otherwise dispose of any of the Placement Agent Warrants or the warrant shares underlying the Placement Agent Warrants for a period of six months following their issuance date, except with the prior written consent of both the Company and the Lead Investor (as defined below in Note 9).
9. Common Stock
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of the preferred stockholders. Through December 31, 2025, no dividends have been declared for shares of common stock.
Private Placement - April 2024
On April 15, 2024, the Company completed a private placement whereby the Company issued 12,660,993 shares of its common stock at a purchase price of $ 2.82 per share, and 1,523,404 prefunded warrants at a purchase price of $ 2.819 per share (which is equal to the price per share less the $ 0.001 exercise price per warrant share). The aggregate net proceeds received by the Company from the offering was $ 37,051 , net of $ 2,948 of underwriting discounts and commissions and offering expenses payable by the Company.
F-21
Table of Contents
Private Placement – October 2025
Securities Purchase Agreement
On October 6, 2025, the Company entered into a Securities Purchase Agreement with Winklevoss Treasury Investments, LLC (“Winklevoss Capital”) as Lead Investor (the “Lead Investor”) and the other investors named therein, for the private placement of (i) 15,212,311 shares of Company common stock, par value $ 0.001 per share, at an offering price of $ 0.52064 per share (the “October 2025 Shares”), (ii) pre-funded warrants (the “October 2025 Pre-Funded Warrants”) to purchase up to an aggregate of 80,768,504 shares of the Company’s common stock at an offering price of $ 0.51964 per Pre-Funded Warrant, each exercisable for one share of common stock at the exercise price of $ 0.001 per Pre-Funded Warrant Share and (iii) common warrants (the “October 2025 Common Warrants”) to purchase up to an aggregate of 71,985,605 shares of Company common stock, each exercisable for one share of common stock at an exercise price of $ 0.5335 per common warrant share. The shares of common stock, together with the common warrants, had an aggregate purchase price of $ 0.61439 per unit, and the pre-funded warrants, together with the common warrants had an aggregate purchase price of $ 0.61339 per unit. The October 2025 Private Placement closed on October 8, 2025. The aggregate gross proceeds received by the Company from the offering was $ 58,888 and after fees and offering expenses payable by the Company the net proceeds were $ 57,170 .
Lead Investor Agreement
In connection with the Securities Purchase Agreement, the Company entered into a Lead Investor Agreement, dated October 6, 2025 (the “Lead Investor Agreement”) with Winklevoss Capital to secure its commitment as Lead Investor in the October 2025 Private Placement. Winklevoss Capital beneficially owns 19.9 % of the common stock of the Company, excluding certain shares of common stock that may in the future become exercisable under the October 2025 Pre-Funded Warrants and October 2025 Common Warrants. Pursuant to the Lead Investor Agreement, as of the Closing Date, the Board of Directors of the Company (the “Board”) increased the size of the Board to twelve members. On November 11, 2025, the Board appointed each of Mr. Khing Oei and Mr. William McEvoy as a director of the Board, with Mr. Oei appointed as a Class II director and to serve in such capacity until the 2028 annual meeting of stockholders, and with Mr. McEvoy appointed as a Class III director and to serve in such capacity until the 2026 annual meeting of stockholders, or until the earlier of such director’s death, resignation or removal. Mr. Oei was also elected to serve as non-executive Chairman of the Board, effective as of November 11, 2025. Concurrently with Mr. Oei’s appointment, Christopher Mirabelli, PhD, stepped down from his role as Chairman, while remaining a member of the Board.
Issuance of Common Stock under Sales Agreement — November 2025
During the year ended December 31, 2025, the Company entered into a Sales Agreement with Cantor, pursuant to which the Company may offer and sell shares of its common stock, par value $ 0.001 per share, having an aggregate offering price of up to $ 200,000 from time to time to or through Cantor, acting as principal and/or sales agent.
Subject to the terms and conditions of the Sales Agreement, Cantor will use its commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of the Nasdaq Capital Market to sell the Shares pursuant to the Offering from time to time, based upon the Company’s instructions, including any price, time or size limits specified by the Company. The Company has provided Cantor with customary indemnification and contribution rights in favor of Cantor, and Cantor earns a commission of 1.5 % of the gross proceeds from each sale of the Shares pursuant to the Sales Agreement.
The Company has no obligation to sell any of the Shares and may at any time suspend offers under the Sales Agreement. The Company and Cantor may each terminate the Sales Agreement at any time upon ten business days prior notice.
During the year ended December 31, 2025, the Company issued 27,151,211 shares of its common stock under the Sales Agreement, for net proceeds of $ 51,818 , net of commissions of $ 789 . Deferred offering costs in connection with the Sales Agreement were $ 544 , of which $ 143 were amortized during the year ended December 31, 2025.
F-22
Table of Contents
10. Stock-Based Compensation
Equity Incentive Plans
On January 20, 2017, the Company’s stockholders approved the 2016 Equity Incentive Plan (the “2016 Plan”). Beginning on January 1, 2018, the number of shares of common stock authorized for issuance pursuant to the 2016 Plan was increased each January 1 by an amount equal to four percent ( 4 %) of the Company’s outstanding common stock as of the end of the immediately preceding calendar year or such other amount as determined by the compensation committee of the Company’s board of directors.
On June 16, 2022, the Company’s stockholders approved the 2022 Equity Incentive Plan (the “2022 Plan”), which provided for a total of 750,000 new shares of the Company’s common stock to be granted. In addition, on June 16, 2023, and July 2, 2024, stockholders approved new shares of the Company’s common stock to be added to the 2022 Plan for future issuance of 2,250,000 and 2,000,000 , respectively.
On December 15, 2025, the Company held a special meeting of stockholders (the “Special Meeting”). The Company’s stockholders voted to approve the adoption of the Company’s 2025 Equity Incentive Plan (the “2025 Plan”) at the Special Meeting, and the 2025 Plan became immediately effective upon such approval. The 2025 Plan, among other matters, provides for a total of 31,454,785 shares of the Company’s common stock, $ 0.001 par value per share that can be covered by grants, as may be adjusted from time to time on the terms described therein. Also in connection with the Special Meeting, the Company increased it’s authorized shares from 250,000,000 shares to 500,000,000 shares ( 490,000,000 shares are designated as Common Stock).
As of December 31, 2025, there were 9,344,326 shares available for grant under the Company’s Equity Incentive Plans.
A summary of stock option activity under the Company’s Equity Incentive Plans is as follows:
Weighted
Average
Weighted
Aggregate
Exercise Price
Average Remaining
Intrinsic
Options
Per Share
Life in Years
Value
Outstanding at December 31, 2023
3,384,366
$
13.97
8.40
Granted
3,460,000
$
2.57
Exercised
( 34,698 )
$
2.68
Forfeited
( 392,924 )
$
4.98
Outstanding at December 31, 2024
6,416,744
$
8.43
8.43
Granted
1,000,000
$
1.18
Exercised
( 6,667 )
$
2.40
Forfeited
( 3,652,839 )
$
7.45
Outstanding at December 31, 2025
3,757,238
$
7.46
7.28
$
—
Options exercisable at December 31, 2025
2,417,888
$
10.76
6.01
Options vested and expected to vest at December 31, 2025
3,757,238
$
7.46
7.28
$
—
The grant date fair value of the options granted during the years ended December 31, 2025 and 2024 was estimated at the date of grant using the Black-Scholes option valuation model. The expected life was estimated using the “simplified” method as defined by the SEC’s Staff Accounting Bulletin 107, Share-Based Payment. The expected volatility was based on the historical volatility of the Company. The risk-free interest rate was based on the continuous rates provided by the U.S.
Treasury with a term approximating the expected life of the option. The expected dividend yield was 0 % because the Company does not expect to pay any dividends for the foreseeable future. The Company elected the straight-line attribution method in recognizing the grant date fair value of options issued over the requisite service periods of the awards, which are generally the vesting periods.
The weighted average grant date fair value for the stock options granted during the years ended December 31, 2025 and 2024 was $ 1.00 and $ 2.04 per share, respectively.
F-23
Table of Contents
The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors during the years ended December 31, 2025 and 2024 were as follows, presented on a weighted average basis:
Year Ended December 31,
2025
2024
Expected volatility
103.46
%
93.92
%
Weighted average risk-free interest rate
3.90
%
3.82
%
Expected dividend yield
0.00
%
0.00
%
Expected term (in years)
7.00
6.46
Stock options generally vest over a three or four year period, as determined by the compensation committee of the board of directors at the time of grant. The options expire ten years from the grant date. As of December 31, 2025, there was approximately $ 1,650 of unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a remaining weighted-average period of approximately 1.67 years.
Restricted Stock Units
During the year ended December 31, 2025, the Company granted 20,799,921 RSUs to employees with a weighted average grant date fair value of $ 0.98 per share. The Company did not grant any RSUs during the year ended December 31, 2024.
The following table presents RSU activity under the Company’s Equity Incentive Plans as of December 31, 2025:
Weighted
Number of
Average Grant
Shares
Date Fair Value
Outstanding at December 31, 2023
262,500
$
19.97
Vested
( 27,500 )
$
25.70
Cancelled
( 15,000 )
$
17.80
Outstanding at December 31, 2024
220,000
$
19.40
Vested
( 303,000 )
$
14.21
Granted
20,799,921
$
0.98
Cancelled
( 2,411,700 )
$
0.44
Outstanding at December 31, 2025
18,305,221
$
1.05
As of December 31, 2025, there were 18,305,221 shares outstanding covered by RSUs that were vested and expected to vest with a weighted average grant date fair value of $ 1.05 per share and an aggregate grant date fair value of $ 19,220 . As of December 31, 2025, there was approximately $ 17,610 of unrecognized compensation costs related to RSUs granted to employees, which are expected to be recognized as expense over a remaining weighted average period of 2.77 years.
The Company recognized stock-based compensation expense related to the issuance of stock option awards and RSUs to employees and non-employees in the consolidated statements of operations during the years ended December 31, 2025 and 2024 as follows:
Stock Based Compensation Expense
Year Ended
December 31,
2025
2024
Research and development
$
1,031
$
2,855
General and administrative
3,868
2,649
Total
$
4,899
$
5,504
F-24
Table of Contents
11. Income Taxes
The provision for income taxes for the year ended December 31, 2025 is due to unrealized gains and losses on investments in the U.S. and based on the results of the Company’s foreign subsidiary in Australia. The provision for income taxes for the year ended December 31, 2024 was based on the results of the Company’s foreign subsidiary in Australia.
Income (loss) before income taxes consisted of the following:
Year Ended
December 31,
2025
2024
U.S.
$
9,639
$
( 69,475 )
Foreign
438
2,505
Income (loss) before income taxes
$
10,077
$
( 66,970 )
A summary of the Company’s current and deferred expense for income tax is as follows:
Year Ended
December 31,
2025
2024
Current expense:
Federal
$
—
$
—
State
—
—
Foreign
137
585
Total current expense:
$
137
$
585
Deferred expense:
Federal
$
2,117
$
—
State
3,001
—
Foreign
—
—
Total deferred expense
$
5,118
$
—
Total income tax expense
$
5,255
$
585
F-25
Table of Contents
A reconciliation of the Company’s statutory income tax rate to the Company’s effective income tax rate is as follows:
Year Ended December 31,
Year Ended December 31,
2025
2024
Amount
Percent
Amount
Percent
Pretax Income (Loss)
$
10,077
$
( 66,970 )
US Federal Statutory Tax Rate
2,116
21.0
%
( 14,064 )
21.0
%
State taxes, net of federal benefit
3,001
29.8
%
—
0.0
%
Foreign Tax Effects:
Australia
Other
( 3 )
0.0
%
131
( 0.2 )
%
Change in valuation allowance
11
0.1
%
( 71 )
0.1
%
Research and development credits
38
0.4
%
—
0.0
%
Tax Credits:
Research and development credits
( 631 )
( 6.3 )
%
( 1,558 )
2.3
%
Change in valuation allowance
638
6.3
%
15,358
( 22.9 )
%
Nontaxable or Nondeductible Items:
Other
17
0.2
%
409
( 0.6 )
%
Share based compensation
3,124
31.0
%
380
( 0.6 )
%
Other Adjustments:
Sec. 382 tax attribute adjustments
( 3,056 )
( 30.4 )
%
—
0.0
%
Total
$
5,255
52.1
%
$
585
( 0.9 )
%
The impact of state and local income taxes, net of federal income tax benefit, relates entirely to the Company’s naked credit, discussed below, and is attributable to Massachusetts.
The components of the Company’s deferred tax assets and liabilities are as follows (in thousands):
Year Ended December 31,
2025
2024
Deferred tax assets:
Federal net operating loss carryforwards
$
17,866
$
8,865
State net operating loss carryforwards
5,253
2,741
Research and development (R&D) tax credits
579
3,488
Capitalized R&D expenses
32,309
23,554
Start-up costs
9,583
10,386
Stock based compensation
3,962
6,696
Accrued expenses
70
911
License fees
—
505
Other
405
403
Total deferred tax assets before valuation allowance
70,027
57,549
Valuation allowance
( 61,559 )
( 57,549 )
Total deferred tax assets after valuation allowance
8,468
—
Deferred tax liabilities:
Unrealized gain on digital asset receivable
( 13,586 )
—
Total deferred tax liabilities
( 13,586 )
—
Net deferred tax assets (liabilities)
$
( 5,118 )
$
—
The Company’s net deferred tax liability of $ 5,118 is what is commonly referred to as a “naked credit” or “hanging credit”. A naked credit exists when a Company is subject to a valuation allowance and maintains a deferred tax liability that cannot be considered as a source of future taxable income for valuation allowance purposes, either because its reversal is indefinite in nature or otherwise. The result of a naked credit is a deferred tax liability that remains on the balance sheet. In future years, if the naked credit
F-26
Table of Contents
can be offset by deferred tax assets, the reversal will be recorded as a benefit through the profit and loss statement. The Company will continue to assess and evaluate strategies that will enable the deferred tax asset, or portion thereof, to be utilized, and will reduce the valuation allowance appropriately at such time when the “more likely than not” criteria is satisfied. The Company notes that the balance currently recorded is in relation to unrealized gains on the Company’s cryptocurrency investments.
As of December 31, 2025, the Company had federal and state net operating loss (“NOL”) carryforwards of approximately $ 85,074 and $ 86,922 respectively. The Company’s federal NOL’s can be carried forward indefinitely and the state NOL’s begin to expire in 2032.
Under Internal Revenue Code Section 382, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. The Company has completed a study to assess whether an ownership change occurred or whether there had been multiple ownership changes since the Company became a “loss corporation” as defined in Section 382. The Company experienced multiple ownership changes occurring in 2019, 2020, 2023, and 2025. The ownership changes have and will continue to subject the Company’s pre-ownership change NOL carryforwards to an annual limitation, which will significantly restrict its ability to use them to offset taxable income in periods following the ownership changes. In general, the annual use limitation equals the aggregate value of the Company’s stock at the time of the ownership change multiplied by a specified tax-exempt interest rate. The latest ownership change in 2025, results in an annual limitation of $ 858,217 . The Company determined it will not be able to utilize its pre 2025 change federal R&D credits before expiration and consequently, has written these off. As a result, during the year ended December 31, 2025, the Company has reduced its deferred tax assets related to the federal R&D credits which is offset by a corresponding decrease in the valuation allowance.
In addition, As of December 31, 2025, the Company has federal and state R&D tax credits of approximately $ 145 and $ 549 , respectively, that begin to expire in 2043 and 2038, respectively, for federal and state tax purposes.
As of December 31, 2025 and 2024, the Company has provided a valuation allowance against its net deferred tax assets, as realization of any associated tax benefit in the future is not more likely than not. The valuation allowance increased by $ 4,010 and decreased by $ 19,307 during the years ended December 31, 2025 and 2024, respectively.
The One Big Beautiful Bill Act (“OBBBA”) was passed and became effective for the Company during 2025. The legislation includes, among other provisions, permanent full expensing for certain business assets, changes to the interest deduction limitation under Section 163(j), amendments to international tax provisions including the global intangible low-taxed income (“GILTI”) and foreign-derived intangible income (“FDII”) regimes, the permanent extension of the controlled foreign corporation (“CFC”) look-through rule, as well as modifications to the treatment of research and development expenditures mentioned above.
Congress modified the treatment for research and development expenditures by adding new Section 174A, which applies for tax years beginning after December 31, 2024. Section 174A permits the immediate deduction of domestic R&D expenditures or, at the taxpayer’s election, capitalization and amortization over a period of at least five years beginning when the related benefits are first realized. Foreign R&D expenditures continue to be capitalized and amortized over 15 years. Transition provisions allow taxpayers either to continue amortizing amounts capitalized under the TCJA rules or to deduct remaining unamortized domestic R&D expenditures in the first tax year beginning after December 31, 2024. The Company has elected to continue amortizing previously capitalized domestic R&D expenditures over the remaining amortization period permitted under OBBBA.
The Company follows the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. As of December 31, 2025, the Company has not recorded any uncertain tax positions.
The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The earliest tax years that may be subject to examination by jurisdiction are 2020 for both federal and state purposes. The Company’s policy is to record interest and penalties related to income taxes as part of the tax provision. There were no interest and penalties pertaining to uncertain tax positions for the years ended December 31, 2025 or 2024.
F-27
Table of Contents
The Company does not provide for U.S. Federal, state, and applicable foreign income and withholding taxes on the financial reporting basis over the tax basis of its foreign subsidiary investment because the Company does has the intentions and ability to indefinitely reinvest the undistributed earnings of its foreign subsidiaries. As a result, deferred taxes have not been recorded for the outside basis differences in its foreign subsidiary as of December 31, 2025 to the extent such differences are expected to result in future taxable income upon repatriation. The Company reviews its ability and intentions to indefinitely reinvest its foreign earnings at each balance sheet.
The Company paid $ 237 of income taxes related to profits in Australia during the year ended December 31, 2025.
12. Net Income (Loss) Per Share
Basic and diluted net income (loss) per share for the years ended December 31, 2025 and 2024 was calculated as follows:
Year Ended December 31,
2025
2024
Numerator:
Net income (loss)
$
4,822
$
( 67,555 )
Dividend attributable to down round feature of warrants
—
( 234 )
Net income (loss) attributable to common stockholders for basic and diluted income (loss) per share
$
4,822
$
( 67,789 )
Denominator:
Weighted average number of common shares outstanding - basic
66,140,346
37,550,677
Weighted average effect of potentially dilutive securities:
Effect of potentially dilutive common stock warrants
4,407,074
—
Effect of potentially dilutive restricted stock units
124,938
—
Weighted average common shares outstanding — diluted
70,672,358
37,550,677
Net income (loss) per share attributable to common stockholders:
Basic
$
0.07
$
( 1.81 )
Diluted
$
0.07
$
( 1.81 )
Included within weighted average common shares outstanding for the years ended December 31, 2025 and 2024, are 80,773,954 , and 2,945,175 common shares issuable upon the exercise of the pre-funded warrants and penny warrants, as the warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net income (loss) per share attributable to common stockholders.
The Company’s potentially dilutive securities include RSUs, stock options and warrants. The following table includes the potential common shares of common stock, presented based on amounts outstanding at each period end, that were excluded from the computation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Year Ended December 31,
2025
2024
Restricted stock units to purchase common stock
14,048,733
220,000
Options to purchase common stock
3,757,238
6,416,744
Warrants to purchase common stock
2,612,667
3,336,146
20,418,638
9,972,890
13. Commitments and Contingencies
Insurance Financing Agreement— In March 2025, the Company entered into an insurance premium financing and security agreement with Aon Premium Finance, LLC. Under the agreement, the Company financed $ 440 of insurance premiums at a 8.74 % fixed annual interest rate. Payments of approximately $ 42 are due monthly through February 2026. As of December 31, 2025, the outstanding principal of the loan had been paid in full.
F-28
Table of Contents
License and Service Agreements— On January 3, 2011, the Company entered into a license agreement with Eli Lilly and Company (“Lilly”), to grant a license to the Company for certain intellectual property rights relating to pharmaceutically active compounds that may be useful in the treatment of bone healing, cancer and, potentially, other medical conditions. As defined in the license agreement, the Company would be required to pay royalties to Lilly based upon a percentage in the low single digits of net sales of developed products, if and when achieved. However, there can be no assurance that clinical or commercialization success of developed products will occur, and no royalties have been paid or accrued through December 31, 2025.
Collaboration Agreement --On August 10, 2020, the Company entered into a collaboration agreement with Adimab, LLC (the “Adimab Agreement”), pursuant to which Adimab will conduct research programs to develop monoclonal antibodies to certain targets identified by the Company and provide it with an option to acquire exclusive rights to such antibodies. Upon payment of an option fee, on a product-by-product basis, Adimab will grant the Company a world-wide, exclusive license for, or assign ownership to the Company of, certain intellectual property rights and grant the Company a non-exclusive license with respect to the Adimab platform technology. As defined in the Adimab Agreement, after exercising an option and making the option payment, the Company would be required to pay Adimab milestones upon the completion of clinical development and regulatory milestones, along with a royalty in the low-single digits of net sales of each product, if and when achieved. However, there can be no assurance that clinical, or commercialization success will occur, and no royalties have been paid or accrued through December 31, 2025.
Legal Proceedings— At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to its legal proceedings. As of the date of this report, the Company is not currently a party to any material legal proceedings.
Indemnification Agreements— In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2025 and 2024.
14. Defined Contribution Plan
The Company has a 401(k) defined contribution plan (the “401(k) Plan”) for substantially all of its employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits.
The Company makes matching employee contributions in cash to the 401(k) Plan at a rate of 100 % of the first 3 % of earnings contributed and 50 % of the next 2 % of earnings contributed.
Employees participating in the 401(k) Plan are fully vested in the Company matching contributions, and investments are directed by participants. The Company made matching contributions of $ 276 and $ 471 for the years ended December 31, 2025 and 2024, respectively.
15. Related Party Transactions
Gemini Space Station, LLC (“Gemini”) is a digital asset trading platform and an affiliate of Winklevoss Capital. Winklevoss Capital is an investor in the Company (See Note 9.) and, as a result, Gemini is considered a related party. During the year ended December 31, 2025, the Company purchased 290,062.67 ZEC tokens at a weighted average cost of $ 334.41 per token, for an aggregate purchase price of $ 97,000 through Gemini. (See Note 3.)
F-29
Table of Contents
16. Subsequent Events
ATM Sales
During the period from January 1, 2026 until March 11, 2026, the Company has issued 6,128,568 shares of its common stock under the Sales Agreement with Cantor, for net proceeds of $ 4,156 .
ZEC Purchases
During the period from January 1, 2026 until March 11, 2026, the Company purchased an additional 4,680.43 ZEC tokens at an average purchase price of $ 427.31 through Gemini.
Change in Fair Value of Embedded Derivative
During the period from January 1, 2026 until March 11, 2026, the price of ZEC has been volatile and has seen significant declines, ranging from high prices of above $ 500 to low prices of below $ 200 . A ZEC price at the end of the three month period ended March 31, 2026 that is lower than the price used for the Company’s financial statements as of December 31, 2025, will result in a decrease in the fair value of the embedded derivative and increase the Company’s net loss for the period. For example, if the Company were to hold the same amount of ZEC at the end of the three month period March 31, 2026 as it held as of March 11, 2026, and the price of ZEC were $ 200 as of March 31, 2026, then the current value of the Company’s digital asset receivable would be approximately $ 59,000 and there would be an unrealized net loss on the change in fair value of the embedded derivative for the three month period ended March 31, 2026 of approximately $ 88,500 . As ZEC is highly volatile, there can be no assurance that the price of ZEC may not decline further, resulting in a smaller digital asset receivable and larger unrealized net loss.
ZODL Investment
On March 9, 2026, the Company announced an investment of $ 5,000 in Znewco, Inc., doing business as Zcash Open Development Lab (ZODL), through a Simple Agreement for Future Equity (“SAFE”) as part of an over $ 25,000 financing of ZODL. The Company’s investment in ZODL will convert into preferred stock as part of a future transaction in which ZODL issues and sells preferred stock at a fixed valuation, or, if there is a liquidity event or dissolution event before the conversion of the SAFE, will become payable for a portion of the proceeds of such liquidity event or dissolution.
Nasdaq Closing Bid Price Deficiency Letter
On March 4, 2026, the Company received a notification letter (the “ Closing Bid Price Deficiency Letter ” ) from the Listing Qualifications staff of The Nasdaq Stock Market LLC ( “ Nasdaq ” ) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company ’ s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) ( “ Rule 5550(a)(2) ” ). The Closing Bid Price Deficiency Letter is a notice of deficiency, not delisting, and does not currently affect the listing or trading of the Company ’ s shares of common stock on The Nasdaq Capital Market.
F-30